About Sermorelin Legit.

What this site is

Sermorelin Legit is a verification console for the GHRH(1-29) record — every regulatory and research claim on the site is wired back to a primary source a reader can check, so the trail can be audited rather than taken on faith. It publishes; it does not practice or supply. No clinic, prescriber, or storefront stands behind it, and it offers no diagnosis, dosing, or treatment advice. The 'legit' in the name is about whether a claim can be sourced — not a promise about any product, which this site does not sell.

The design borrows the grammar of an operations console on purpose: every regulatory and evidentiary fact is presented as a verifiable status with a provenance string, rather than as a marketing assertion. When the record says a finding belongs to the related analog tesamorelin, we mark it as tesamorelin. When the long-term adult data are thin, we leave that gap visible rather than papering over it.

Why "legit"

The word "legit" in the domain name is editorial framing, not a legal or quality claim about any seller. The "legit" question people bring to sermorelin is really a due-diligence question: is it real, was it ever FDA-approved, what is its current standing? Those are answerable from the public record, and that is what this site does — it reads the regulatory and research facts straight.

What we can verify, we state with its source: sermorelin was FDA-approved as a prescription GHRH analog (NDA 020443) for pediatric growth hormone deficiency, was withdrawn from the US market in 2008 for commercial reasons, and is now compounded under FDA's interim Category 1 Section 503A policy. We do not make claims about the legitimacy of any particular vendor, and the modifier is a position this publisher occupies relative to the literature, not a statement about the site's services.

How we handle the evidence

Every quantitative claim on this site maps to a numbered citation with a PMID or DOI. We separate what the published evidence establishes (the pediatric height-velocity acceleration, the older-men GH/IGF-1 reversal) from what is mechanistically plausible but unproven (general adult muscle-building, weight loss), and from hypothesis-generating frontier signals (cardiac-repair and in-silico glioma findings). We describe research findings only; we do not recommend doses for human use, and we name no product brands.